GenScript Biotech entered into an agreement with InnoBation Co. Ltd. for the cell line development and engineering of GMP plasmids and lentivirus. Through this agreement, GenScript is aiming to provide CRO services to InnoBation by using CRISPR and CAS gene technology.
University of Connecticut Health Center developed “All-In-One Dual CRISPR-Cas 12a (AIOD-CRISPR)” assay method, which performs ultrasensitive, specific, and visual detection of nucleic acid in the SARS-COV-2 virus and can test for COVID-19 infection at a quicker pace.
Mammoth Biosciences, Inc. developed a new CRISPR technology-based test for COVID- 19 detections called “SARS-COV-2 DETECTR”, which can take out results within an hour of the test using loop-mediated amplification and CAS12 enzyme.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3287
Published Date: Apr 26, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The rising applications of CRISPR and CAS gene technology and the increasing government and private funding for medical research are the key factors driving the market growth.
The market size of CRISPR and CAS gene technology is anticipated to attain a CAGR of 30% over the forecast period, i.e., 2023-2035.
The high cost of investment, time consumption, and pending patent concerns and outcomes of clinical trials are estimated to be the growth hindering factors for the market expansion.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The major players in the market are Thermo Fisher Scientific Holdings, Inc., Origene Technologies, Addgene, Inc., Merck KGaA, GenScript Biotech, Cellecta, Inc, Caribou Bioscience, Inc., Horizon Discovery Group, Mammoth Biosciences, Inc., Inscripta, Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, product, end user, and by region.
The biomedical segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.